Immunome Inc. (IMNM)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.49 per share a year ago.
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Immunome Inc. (IMNM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunome Inc. ever had a stock split?
Immunome Inc. Profile
| Biotechnology Industry | Healthcare Sector | Clay B. Siegall CEO | NASDAQ (CM) Exchange | 45257U108 CUSIP |
| US Country | 131 Employees | - Last Dividend | - Last Split | 2 Oct 2020 IPO Date |
Overview
Immunome, Inc. is a pioneering biotechnology company founded in 2006, with a focus on the development of innovative cancer therapies. Based in Bothell, Washington, the company leverages advanced research and technology to create treatments that target specific cancer types, aiming to improve patient outcomes and quality of life. Immunome, Inc. stands at the forefront of cancer research, pushing the boundaries of scientific discovery to develop therapies that can significantly impact the lives of patients battling cancer.
Products and Services
- AL102
An investigational gamma secretase inhibitor, AL102 is currently undergoing a Phase 3 clinical trial for its efficacy in treating desmoid tumors. Desmoid tumors, although benign, can be aggressive and invasive, making AL102 a critical component of Immunome, Inc.'s portfolio as it represents a significant step towards offering new solutions for patients with few treatment options.
- IM-1021
This preclinical asset is an innovative approach to cancer treatment, focusing on receptor tyrosine kinase-like orphan receptor 1 (ROR1) and antibody-drug conjugates. ROR1 is a promising target for cancer therapy because of its selective expression in cancer cells, particularly in leukemia, breast cancer, and lung cancer. By developing IM-1021, Immunome, Inc. aims to exploit this vulnerability in cancer cells, offering a tailored treatment that could minimize harm to healthy cells.
- IM-3050
As another preclinical asset, IM-3050 targets fibroblast activation protein (FAP) with radioligand therapy. FAP is frequently overexpressed in cancer-associated fibroblasts, which are found in the tumor microenvironment. By targeting these fibroblasts, IM-3050 has the potential to disrupt the tumor's growth and support system, providing a novel angle for cancer therapy that complements existing treatment modalities.
- IM-4320
This ambitious preclinical candidate is an anti-IL-38 immunotherapy. IL-38 has been identified as a potential therapeutic target due to its role in modulating the immune system's response to cancer cells. By developing an immunotherapy that targets IL-38, Immunome, Inc. is exploring a new frontier in cancer treatment that focuses on enhancing the body's natural ability to fight cancer, thereby offering a groundbreaking approach to treatment that could reshape the landscape of cancer therapy.
Contact Information
